Rabbit Recombinant Monoclonal Ornithine Carbamoyltransferase/OTC antibody - conjugated to Alexa Fluor® 555.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Catalyzes the second step of the urea cycle, the condensation of carbamoyl phosphate with L-ornithine to form L-citrulline (PubMed:2556444, PubMed:6372096, PubMed:8112735). The urea cycle ensures the detoxification of ammonia by converting it to urea for excretion (PubMed:2556444).
OTCase, OTC
Rabbit Recombinant Monoclonal Ornithine Carbamoyltransferase/OTC antibody - conjugated to Alexa Fluor® 555.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.
Ornithine Carbamoyltransferase (OTC) also known as ornithine aminotransferase is an enzyme critical in the urea cycle. The OTC protein facilitates the conversion of ornithine and carbamoyl phosphate into citrulline a process essential for nitrogen excretion. The human OTC protein has a mass of approximately 36 kilodaltons and is primarily expressed in the liver mitochondria. Protein assays and procurement efforts often focus on obtaining accurate measurements and ensuring high-purity OTC peptides enabling proper functional studies.
Ornithine carbamoyltransferase plays a significant role in detoxifying ammonia by forming citrulline an important urea cycle intermediate. The protein functions as a homotrimer meaning three identical subunits form an active enzyme complex. This multimeric state facilitates efficient substrate processing allowing effective handling of nitrogen waste. The integral role of OTC in the urea cycle highlights its importance in maintaining systemic nitrogen balance.
OTC is a central component of the urea cycle and influences nitrogen metabolism pathways. These pathways include the conversion of ammonia to urea an important detoxifying process for safe excretion by the kidneys. OTC closely interacts with enzymes such as argininosuccinate synthetase highlighting the coordinated action required to advance urea formation. Understanding OTC's participation within these pathways helps identify its regulatory points and the potential impact of genetic variations.
Mutations in the OTC gene can lead to ornithine transcarbamylase deficiency a disorder affecting ammonia detoxification. This X-linked genetic condition disrupts normal nitrogen metabolism causing ammonia accumulation particularly harmful to the central nervous system. OTC deficiency shares a functional relationship with other urea cycle disorders such as citrullinemia due to its contribution to the same biochemical pathway. Researchers focus on identifying OTC protein mutations to improve diagnosis and treatment of these conditions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com